Journals / Kafkas Journal of Medical Sciences / 2017 / Yıl: 2017 Sayı: 1

Bortezomib Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma

Multipl Myelomalı Bir Hastada Bortezomib İlişkili Konjestif Kalp Yetmezliği

Pages
78–80
Publication Date
2017-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient’s symptoms improved and the ejection fraction normalized after three months following discontinuation of bortezomib.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bortezomib is a proteasome inhibitor commonly used for the treatment of multiple myeloma, and it has some cardiac side effects.
📊
Key Findings & Data:We describe a 82-year-old patient with International Staging System Stage III multiple myeloma.
💡
Conclusion & Impact:The patient’s symptoms improved and the ejection fraction normalized after three months following discontinuation of bortezomib.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:bortezomib · konjestif kalp yetmezliği · multipl myeloma

Abstract

Bortezomib is a proteasome inhibitor commonly used for the treatment of multiple myeloma, and it has some cardiac side effects. The incidence of cardiac failure associated with bortezomib therapy in clinical trials remains incidental. We describe a 82-year-old patient with International Staging System Stage III multiple myeloma. Combined chemotherapy with bortezomib 1.3 mg/m2 on days 1, 8, 15, 22 of each cycle and 40 mg/day dexamethasone (days 1 to 4) was started to him. Two days after the end of the 3rd cycle of chemotherapy (12th dose of bortezomib), he admitted with mild edema of bilateral lower extremity. Echocardiography revealed a drop in the left ventricular ejection fraction from pretreatment levels of >55% to 30–35%. Therefore; bortezomib treatment was postponed and he was treated for congestive heart failure. The patient’s symptoms improved and the ejection fraction normalized after three months following discontinuation of bortezomib.

Özet

Bortezomib genellikle multipl myeloma tedavisi için kullanılan bir proteazom inhibitörüdür ve bazı kardiyak yan etkilere sahiptir. Klinik çalışmalardaki bortezomib tedavisiyle ilişkili kalp yetmezliği insidansı tesadüfi olarak kalır. Biz Uluslararası skorlama sistemine göre Evre 3 multipl myeloması olan 82 yaşında bir hastayı sunuyoruz. Bu hastaya kombine kemoterapi (her bir siklusta bortezomib 1,3 mg/m2 D1, D8, D15, D22 ve 40 mg/gün deksametazon [D1–4]) başlandı. Kemoterapisinin 3 siklusunun tamamlanmasından 2 gün sonra (bortezomib tedavisinin 12. dozu) hasta bilateral alt extremitelerde hafif ödem nedeniyle başvurdu. Ekokardiyografide ejeksiyon fraksiyonun tedavi öncesi >%55’den %30–35’e düştüğünü gösterdi. Bu nedenle bortezomib tedavisi kesildi ve konjestif kalp yetmezliği için hasta tedavi edildi. Bortezomib kesilmesinden 3 ay sonra hastanın klinik semptomları düzeldi ve ejeksiyon fraksiyonu normale döndü.

🔖

Cite This Article

Sincan, G., Bilen, Y., Erdem, F., Sincan, S., Aksakal, E. (2017). Bortezomib Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma. Kafkas Journal of Medical Sciences, Yıl: 2017 Sayı: 1, 78–80. https://ajindex.com/articles/892195

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...